Escriba para buscar

Buscar Noticias es mi negocio

En resumen

Puerto Rico-based LemVega Capital launches Biotech Venture Fund III

The plaintiffs are also seeking injunctions to bar the defendants from contacting LemVega’s clients, partners or staff, and from making further defamatory statements.

San Juan-based LemVega Capital, a minority- and women-owned private investment management firm, has announced the launch of its third fund, a new venture focused on the “dynamic and rapidly evolving” biotechnology sector.

LemVega Capital Biotech Venture Fund III, co-founded by Asmita Kulkarni and Caroline Farah Lembck, has as its primary focus startups developing innovative solutions in bioengineering, bioremediation, tissue regeneration, stem cell and gene therapy, plant-derived therapeutics, and psychedelic therapeutics.

LemVega Capital has built a reputation for delivering success with its inaugural Fund I and follow-up Fund II.

The new fund is crafted with a vision to identify, invest in and foster the growth of early-stage biotech startups, especially those spearheaded by underrepresented entrepreneurs with trailblazing ideas and discoveries, the women said.

The co-founders said the fund offers an investment opportunity that promises growth potential while fostering a future that is inclusive, diverse and equitable.

“We bring to the table a wealth of deep industry knowledge, broad networks and disciplined risk management approaches, enabling us to discover opportunities that resonate with our dedication to revolutionizing health care and improving the lives of people around the globe,” said Kulkarni, whose background in biotechnology and leadership in a life-sciences-focused intellectual property consulting firm provide a unique perspective to the venture fund.

Lembck added that “investing in LemVega Capital’s Biotech Venture Fund offers investors an opportunity to be a part of transforming the biotech landscape, not just in Puerto Rico, but on a global scale. Our objective is to cultivate a portfolio of avant-garde biotech companies that can make a significant positive impact on the world, while concurrently delivering substantial returns to our investors.”

With its base in Puerto Rico, LemVega Capital benefits from incentives for biotech companies, rendering it a “prime location for investment and business growth.”

Detalles del autor
Detalles del autor
Esta historia fue escrita por nuestro personal basándose en un comunicado de prensa.
Etiquetas:

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *.

¡Oh, oh! Parece que estás usando un bloqueador de anuncios.

Nuestro sitio web depende de los anuncios para ofrecer contenido gratuito y mantener nuestras operaciones. Al desactivar su bloqueador de anuncios, nos ayuda a seguir ofreciendo contenido valioso sin ningún costo para usted.

Agradecemos sinceramente su comprensión y apoyo. Gracias por considerar desactivar su bloqueador de anuncios para este sitio web.